ORG Wealth Partners’s Cytek Biosciences CTKB Stock Holding History

ORG Wealth Partners’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$464	Buy	+78	New	+$370	﹤0.01%	2097

Other funds holding CTKB

Boston Partners Boston, Massachusetts $111B AUM 30.48% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Royce & Associates New York $11B AUM 39.4% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

ORG Wealth Partners's CTKB Position: Q3 2026 in Review

ORG Wealth Partners opened a new position in Cytek Biosciences (CTKB) in Q3 2026: 78 shares worth $464. The stake represents ﹤0.01% of the portfolio and ranks #2097 among its holdings.

97 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.

ORG Wealth Partners held 78 shares of Cytek Biosciences worth $464 as of Q3 2026.
Cytek Biosciences was a new ORG Wealth Partners position in Q3 2026.
Cytek Biosciences made up ﹤0.01% of ORG Wealth Partners's portfolio in Q3 2026, its #2097 holding.
97 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.

Based on ORG Wealth Partners's 13F filing for Q3 2026, filed 3 Nov 2026.